Pharmacology

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase

Intravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbanceIntravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbance

Intravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbanceIntravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbance

Intravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbanceIntravenous cyclophosphamide, prednisone, lupus nephritis, tacrolimus, estimated glomerular filtration rate, eGFR, insomnia, emotional disturbance

ginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerolsginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerols

ginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerolsginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerols

ginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerolsginger extract, ICU, enternal nutrition, delayed gastric emptying, adult respiratory distress syndrome, erythromycin, nosocomial pneumonia, bacterial overgrowth, reflux, tracheal colonization, shogaols, gingerols

urogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogenurogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogen

urogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogenurogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogen

urogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogenurogenital, breast cancer, aromatase inhibitors, vaginal atrophy, tamoxifen, estrogen